STOCK TITAN

Alto Neuroscience (ANRO) director Andrew Craig Miller files initial Form 3

(Neutral)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Alto Neuroscience, Inc. director Andrew Craig Miller filed an initial Form 3 reporting his status as a director of the company. The excerpt shows no reported common stock or derivative holdings and no buy, sell, or other insider transactions associated with this filing.

Positive

  • None.

Negative

  • None.
Buy shares reported 0 shares Form 3 transaction summary buyShares
Sell shares reported 0 shares Form 3 transaction summary sellShares
Exercise shares reported 0 shares Form 3 transaction summary exerciseShares
Derivative transactions 0 transactions Form 3 transaction summary derivativeTransactionCount
Form 3 regulatory
"INSIDER FILING DATA (Form 3): {"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
reportingPersons regulatory
""reportingPersons": [ { "name": "Miller Andrew Craig""
transactionSummary financial
""transactionSummary": { "buyCount": 0, "sellCount": 0"
derivativeSummary financial
""derivativeSummary": [],"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does Andrew Craig Miller’s Form 3 for ANRO show?

The Form 3 shows that Andrew Craig Miller is a director of Alto Neuroscience, Inc. In this excerpt, there are no reported common stock or derivative holdings and no insider transactions such as purchases, sales, or option exercises.

Did Andrew Craig Miller buy or sell Alto Neuroscience (ANRO) shares in this Form 3?

No insider share purchases or sales are reported in this Form 3. The transaction summary lists zero buy shares, sell shares, exercises, gifts, tax withholdings, or restructuring entries, indicating no trading activity in this specific filing excerpt.

Are there any derivative securities reported for ANRO in this Form 3?

No derivative securities are shown in this Form 3 excerpt. The derivativeSummary is empty and the transaction summary reports zero derivative transactions and zero exercise shares, indicating no options, warrants, or similar instruments are detailed here.

What is the significance of a Form 3 filing for Alto Neuroscience, Inc. (ANRO)?

A Form 3 is an initial statement of beneficial ownership for company insiders. Here, it mainly records that Andrew Craig Miller is a director of Alto Neuroscience, Inc., with no trades or existing holdings disclosed in the excerpted data.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Miller Andrew Craig

(Last)(First)(Middle)
C/O ALTO NEUROSCIENCE, INC.
650 CASTRO STREET, SUITE 450

(Street)
MOUNTAIN VIEW CALIFORNIA 94041

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
05/27/2026
3. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Remarks:
No securities beneficially owned.
No securities are beneficially owned.
/s/ Erin R. McQuade, Attorney-in-Fact05/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)